Article
MTHFR and TYMS genotypes influence TPMT activity and its differential modulation in males and females.
Clinical biochemistry - 1 Jan 2010
Karas-Kuzelicki Natasa, Milek Miha, Mlinaric-Rascan Irena
Abstract excerpt
OBJECTIVES: TPMT catalyzes the deactivation of the cytostatic drug 6-mercaptopurine used in treatment of cancer. Patients with low levels of TPMT more often experience severe toxic effects when treated with standard doses of 6-mercaptopurine than patients with high levels who, in turn, may experience inadequate treatment. It is therefore very important to assess factors that could influence TPMT activity. DESIGN...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
